IGC Pharma, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $32.1M
- Price
- $0.308
- % Change (Daily % change from the live per-ticker quote feed.)
- +11.11%
- Volume
- 1.9M
About
IGC Pharma, Inc. operates as a pharmaceutical firm, currently in the clinical development phase, dedicated to pioneering novel treatments for Alzheimer's, a debilitating condition. The company's pipeline includes two experimental drug candidates aimed at this disease: IGC-AD1, which is presently undergoing a Phase 2 clinical study for addressing agitation associated with Alzheimer's-related dementia, and TGR-63, which is still in its preclinical stage. Beyond its therapeutic development efforts, IGC Pharma also explores the application of artificial intelligence (AI) to advance Alzheimer's research. Established on April 29, 2005, by Ram Mukunda, the company maintains its principal office in Potomac, Maryland.
Quick stats
Shares outstanding104.4M
Computed float73.5M
Float / shares70.5%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001326205
Websitehttps://igcpharma.com
AI Summary
AI-generated1/25
standardbullishearnings
IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure
IGC Pharma announced its Phase 2 CALMA trial of IGC-AD1 is within six randomizations of enrollment closure, with topline data anticipated in Q4 2026.
Q2 2026 financial results showed revenue of approximately $265,000 and a net loss of $3.0 million, or $0.03 per share. Cash and equivalents were approximately $331,000, supported by a $12 million credit facility with no outstanding debt.
Management converted approximately $1.15 million of debt into 4.27 million shares of common stock at $0.27 per share to reduce obligations and preserve cash.
Red flags
- Low cash balance of $331k